|        |        |        |        |        |
|--------|--------|--------|--------|--------|
|   |   |   |   |   |

|        |                                                                |        |                                      |        |
|--------|----------------------------------------------------------------|--------|--------------------------------------|--------|
|   | New York                                                       |   | 22-1659359                           |   |
|   | (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |   |
|   |                                                           |   |                                 |   |
|   | 170 Mt. Airy Road, Basking Ridge, NJ                           |   | 07920                                |   |
|   | (Address of principal executive offices)                       |   | (Zip code)                           |   |

|        |       |        |      |        |
|--------|-------|--------|------|--------|
|   | Yes x |   | No o |   |

|        |             |        |      |        |
|--------|-------------|--------|------|--------|
|   | Yes o  |   | No o |   |

|                           |        |                           |        |                         |        |                             |
|---------------------------|--------|---------------------------|--------|-------------------------|--------|-----------------------------|
| Large Accelerated Filer o |   | Accelerated Filer o  |   | Non-accelerated Filer o |   | Smaller Reporting Company x |

|        |       |        |      |        |
|--------|-------|--------|------|--------|
|   | Yes o |   | No x |   |

----

|                      |                       |                                                                                                       |          |
|----------------------|-----------------------|-------------------------------------------------------------------------------------------------------|----------|
|                 |                  |                                                                                                  | Page No. |
| PART I –  | Financial Information |                                                                                                  |
|                 |                  |                                                                                                  |     |
|                 | ITEM 1 –        | Financial Statements (unaudited)                                                                      |     |
|                 |                  |                                                                                                  |     |
|                 |                  | Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009                            | 1        |
|                 |                  |                                                                                                  |     |
|                 |                  | Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2010 and 2009 | 2        |
|                 |                  |                                                                                                  |     |
|                 |                  | Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2010 and 2009           | 3        |
|                 |                  |                                                                                                  |     |
|                 |                  | Notes to Unaudited Consolidated Financial Statements                                                  |  4  |
|                 |                  |                                                                                                  |     |
|                 | ITEM 2 –        | Management's Discussion and Analysis of Financial Condition and Results of Operations                 |  14 |
|                 |                  |                                                                                                  |     |
|                 | ITEM 3 –        | Quantitative and Qualitative Disclosures About Market Risk                                            | 29       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 4 –        | Controls and Procedures                                                                               | 29       |
|                 |                  |                                                                                                  |     |
| PART II – | Other Information     |                                                                                                  |
|                 |                  |                                                                                                  |
|                 | ITEM 1 –        | Legal Proceedings                                                                                     | 30       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 1A –       | Risk Factors                                                                                          | 30       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 2 –        | Unregistered Sales of Equity Securities and Use of Proceeds                                           | 31       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 3 –        | Defaults upon Senior Securities                                                                       | 31       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 4 –        | Removed and Reserved                                                                                  | 31       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 5 –        | Other Information                                                                                     | 31       |
|                 |                  |                                                                                                  |     |
|                 | ITEM 6 –        | Exhibits                                                                                              | 31       |
|                 |                  |                                                                                                  |     |
|                 |                  | Signatures                                                                                            | 32       |

----

|                                                                                                                                                                                                                                                                                                       |        |                         |        |                        |          |        |        |        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------|--------|------------------------|----------|--------|--------|--------|
|                                                                                                                                                                                                                                                                                                  |   | September 30, 2010 |   | December 31, 2009 |
| ASSETS (Note 10)                                                                                                                                                                                                                                                                                      |   |                    |   |                   |
| Current assets:                                                                                                                                                                                                                                                                                       |   |                    |   |                   |
| Cash and cash equivalents                                                                                                                                                                                                                                                                             |   | $                       | 18,247 |                   |     | $      | 16,495 |   |
| Accounts receivable, net of allowance for doubtful accounts of $1,015 and $1,237 at September 30, 2010 and December 31, 2009, respectively                                                                                                                                                            |   | 21,505                  |   |                   | 20,365   |   |
| Inventories                                                                                                                                                                                                                                                                                           |   | 2,805                   |   |                   | 2,750    |   |
| Income tax receivable                                                                                                                                                                                                                                                                                 |   | 18                      |   |                   | 1,479    |   |
| Other current assets                                                                                                                                                                                                                                                                                  |   | 1,665                   |   |                   | 2,816    |   |
| Total current assets                                                                                                                                                                                                                                                                             |   | 44,240                  |   |                   | 43,905   |   |
|                                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| Property, plant and equipment at cost                                                                                                                                                                                                                                                                 |   | 48,585                  |   |                   | 45,739   |   |
| Less: Accumulated depreciation and amortization                                                                                                                                                                                                                                                       |   | 37,557                  |   |                   | 34,184   |   |
| Property, plant and equipment, net                                                                                                                                                                                                                                                                    |   | 11,028                  |   |                   | 11,555   |   |
|                                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| Intangible assets, net                                                                                                                                                                                                                                                                                |   | 630                     |   |                   | 932      |   |
| Other assets                                                                                                                                                                                                                                                                                          |   | 329                     |   |                   | 310      |   |
| Total assets                                                                                                                                                                                                                                                                                |   | $                       | 56,227 |                   |     | $      | 56,702 |   |
|                                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| Current liabilities:                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| Accounts payable                                                                                                                                                                                                                                                                                      |   | $                       | 6,497  |                   |     | $      | 5,167  |   |
| Accrued expenses                                                                                                                                                                                                                                                                                      |   | 7,120                   |   |                   | 8,636    |   |
| Total current liabilities                                                                                                                                                                                                                                                                        |   | 13,617                  |   |                   | 13,803   |   |
| Other long-term liabilities                                                                                                                                                                                                                                                                           |   | 1,246                   |   |                   | 1,473    |   |
| Commitments and Contingencies (Note 11)                                                                                                                                                                                                                                                               |   |                    |   |                   |
|                                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| Stockholders' Equity:                                                                                                                                                                                                                                                                                 |   |                    |   |                   |
| Common stock, par value $.04 per share; authorized 240,000,000 shares, issued  69,598,982 shares and 68,713,982  shares as of September 30, 2010 and December 31, 2009, respectively. Outstanding: 69,589,587 shares and 68,704,587 shares at September 30, 2010 and December 31, 2009, respectively. |   | 2,784                   |   |                   | 2,748    |   |
| Additional paid-in capital                                                                                                                                                                                                                                                                            |   | 148,108                 |   |                   | 147,507  |   |
| Accumulated deficit                                                                                                                                                                                                                                                                              |   | (109,457                | )      |                   | (108,758 | )      |
|                                                                                                                                                                                                                                                                                                  |   | 41,435                  |   |                   | 41,497   |   |
| Less: Treasury stock, at cost; 9,395 shares as of  September 30, 2010 and        December 31, 2009                                                                                                                                                                                                    |   | (71                     | )      |                   | (71      | )      |
| Total stockholders' equity                                                                                                                                                                                                                                                                            |   | 41,364                  |   |                   | 41,426   |   |
| Total liabilities and stockholders' equity                                                                                                                                                                                                                                                            |   | $                       | 56,227 |                   |     | $      | 56,702 |   |
|                                                                                                                                                                                                                                                                                                  |   |                    |   |                   |
| See accompanying notes to consolidated financial statements.                                                                                                                                                                                                                                          |   |                    |   |                   |

----

|                                                              |        |                                  |         |                                 |            |        |         |            |        |        |            |        |        |   |         |        |
|--------------------------------------------------------------|--------|----------------------------------|---------|---------------------------------|------------|--------|---------|------------|--------|--------|------------|--------|--------|---|---------|--------|
|                                                         |   | Three Months Ended September 30, |    | Nine Months Ended September 30, |
|                                                         |   | 2010                             |    | 2009                            |       | 2010   |    | 2009       |
| Revenues                                                     |   | $                                | 40,346  |                            |       | $      | 43,790  |       |   | $      | 122,978    |   |   | $ | 137,437 |   |
| Cost of operations                                           |   | 30,064                           |    |                            | 32,272     |   |    | 90,753     |   |   | 100,603    |   |
|  Gross profit                                           |   | 10,282                           |    |                            | 11,518     |   |    | 32,225     |   |   | 36,834     |   |
| Selling, general and administrative expenses                 |   | 10,607                           |    |                            | 11,867     |   |    | 33,292     |   |   | 38,360     |   |
| Restructuring and other charges                         |   | 669                              |    |                            | 261        |   |    | 908        |   |   | 1,139      |   |
|  Operating loss from continuing operations              |   | (994                             | )       |                            | (610       | )      |    | (1,975     | )      |   | (2,665     | )      |
| Other (expense) income:                                      |   |                             |    |                            |       |   |    |       |
| Interest expense                                             |   | (2                               | )       |                            | —    |   |    | (8         | )      |   | (1         | )      |
| Interest income                                              |   | 27                               |    |                            | 22         |   |    | 104        |   |   | 66         |   |
| Other (expense) income, net                                  |   | (73                              | )       |                            | (133       | )      |    | 1,382      |   |   | (334       | )      |
|                                                         |   | (48                              | )       |                            | (111       | )      |    | 1,478      |   |   | (269       | )      |
| Loss from continuing operations before income taxes          |   | (1,042                           | )       |                            | (721       | )      |    | (497       | )      |   | (2,934     | )      |
|                                                         |   |                             |    |                            |       |   |    |       |
| Income tax expense (benefit)                                 |   | 175                              |    |                            | (2         | )      |    | 202        |   |   | 36         |   |
|                                                         |   |                             |    |                            |       |   |    |       |
| Loss from continuing operations                              |   | (1,217                           | )       |                            | (719       | )      |    | (699       | )      |   | (2,970     | )      |
|                                                         |   |                             |    |                            |       |   |    |       |
| Discontinued operations:                                     |   |                             |    |                            |       |   |    |       |
| Loss on sale of subsidiary                                   |   | —                          |    |                            | —    |   |    | —    |   |   | (41        | )      |
| Net loss                                                     |   | $                                | (1,217  | )                               |       | $      | (719    | )          |   | $      | (699       | )      |   | $ | (3,011  | )      |
| Basic and diluted loss per share:                            |   |                             |    |                            |       |   |    |       |
| Continuing operations                                        |   |                             |    |                            |       |   |    |       |
| Basic                                                        |   | $                                | (0.02   | )                               |       | $      | (0.01   | )          |   | $      | (0.01      | )      |   | $ | (0.04   | )      |
| Diluted                                                      |   | $                                | (0.02   | )                               |       | $      | (0.01   | )          |   | $      | (0.01      | )      |   | $ | (0.04   | )      |
| Discontinued operations                                      |   |                             |    |                            |       |   |    |       |
| Basic                                                        |   | $                                | — |                            |       | $      | — |       |   | $      | —    |   |   | $ | — |   |
| Diluted                                                      |   | $                                | — |                            |       | $      | — |       |   | $      | —    |   |   | $ | — |   |
| Net loss                                                     |   |                             |    |                            |       |   |    |       |
| Basic                                                        |   | $                                | (0.02   | )                               |       | $      | (0.01   | )          |   | $      | (0.01      | )      |   | $ | (0.04   | )      |
| Diluted                                                      |   | $                                | (0.02   | )                               |       | $      | (0.01   | )          |   | $      | (0.01      | )      |   | $ | (0.04   | )      |
|                                                         |   |                             |    |                            |       |   |    |       |
| Weighted average number of shares:                           |   |                             |    |                            |       |   |    |       |
| Basic and diluted                                            |   | 69,589,587                       |    |                            | 68,704,587 |   |    | 69,386,528 |   |   | 68,687,994 |   |
|                                                         |   |                             |    |                            |       |   |    |       |
| See accompanying notes to consolidated financial statements. |   |                             |    |                            |

----

|                                                                                                       |                                 |        |        |         |        |         |        |
|-------------------------------------------------------------------------------------------------------|---------------------------------|--------|--------|---------|--------|---------|--------|
|                                                                                                  | Nine Months Ended September 30, |
|                                                                                                  | 2010                            |   | 2009   |
| Cash flows from operating activities:                                                                 |                            |   |   |
| Net loss                                                                                              | $                               | (699   | )      |    | $      | (3,011  | )      |
| Loss from discontinued operations, net of income taxes                                                | —                         |   |   | (41     | )      |
| Loss from continuing operations                                                                       | (699                            | )      |   | (2,970  | )      |
| Adjustments to reconcile loss from continuing operations to net cash                                  |                            |   |   |
| provided by operating activities of continuing operations:                                            |                            |   |   |
| Depreciation                                                                                          | 3,658                           |   |   | 5,096   |   |
| Amortization                                                                                          | 302                             |   |   | 393     |   |
| Provision for bad debt expense                                                                        | 109                             |   |   | 12      |   |
| Share-based compensation expense                                                                      | 484                             |   |   | 484     |   |
| Loss on disposal of fixed assets                                                                      | 135                             |   |   | 178     |   |
| Change in assets and liabilities, net of effect                                                       |                            |   |   |
| from disposition of business:                                                                         |                            |   |   |
| Accounts receivable                                                                                   | (1,249                          | )      |   | 2,447   |   |
| Inventories                                                                                           | (55                             | )      |   | 9       |   |
| Other assets                                                                                          | 1,132                           |   |   | (183    | )      |
| Income tax receivable                                                                                 | 1,461                           |   |   | 12      |   |
| Accounts payable, accrued expenses and other long-term liabilities                                    | (480                            | )      |   | 234     |   |
| Net cash provided by operating activities of continuing operations                                    | 4,798                           |   |   | 5,712   |   |
| Net cash used in operating activities of discontinued operations                                      | —                         |   |   | (300    | )      |
| Net cash provided by operating activities                                                             | 4,798                           |   |   | 5,412   |   |
|                                                                                                  |                            |   |   |
| Cash flows from investing activities:                                                                 |                            |   |   |
| Capital expenditures                                                                                  | (2,993                          | )      |   | (2,463  | )      |
| Net cash used in investing activities of continuing operations                                        | (2,993                          | )      |   | (2,463  | )      |
| Net cash provided by investing activities of discontinued operations                                  | —                         |   |   | 83      |   |
| Net cash used in investing activities                                                                 | (2,993                          | )      |   | (2,380  | )      |
|                                                                                                  |                            |   |   |
| Cash flows from financing activities:                                                                 |                            |   |   |
|      Proceeds from issuance of stock related to employee stock purchase plan | 153                             |   |   | — |   |
| Reduction in capital lease obligations                                                                | (105                            | )      |   | (97     | )      |
| Debt financing fees                                                                                   | (101                            | )      |   | (257    | )      |
| Net cash used in financing activities of continuing operations                                        | (53                             | )      |   | (354    | )      |
| Net cash provided by (used in) financing activities of discontinued operations                        | —                         |   |   | — |   |
| Net cash used in financing activities                                                                 | (53                             | )      |   | (354    | )      |
|                                                                                                  |                            |   |   |
| Net increase in cash and cash equivalents                                                             | 1,752                           |   |   | 2,678   |   |
| Cash and cash equivalents at beginning of period                                                      | 16,495                          |   |   | 11,547  |   |
| Cash and cash equivalents at end of period                                                            | $                               | 18,247 |   |    | $      | 14,225  |   |
|                                                                                                  |                            |   |   |
| Supplemental disclosure of non-cash investing activities:                                             |                            |   |   |
| Fixed assets vouchered but not paid                                                                   | $                               | 462    |   |    | $      | 172     |   |
|      Fixed assets acquired by capital lease                                  | $                               | 50     |   |    | $      | — |   |
| Supplemental disclosure of cash flow information:                                                     |                            |   |   |
| Cash paid during the period for:                                                                      |                            |   |   |
| Interest                                                                                              | $                               | 8      |   |    | $      | 1       |   |
| Income taxes                                                                                          | $                               | 72     |   |    | $      | 40      |   |
|                                                                                                  |                            |   |   |
|                                                                                                  |                            |   |   |
| See accompanying notes to consolidated financial statements.                                          |                            |   |   |

----

----

----

|                                        |        |                                         |        |        |         |        |      |        |
|----------------------------------------|--------|-----------------------------------------|--------|--------|---------|--------|------|--------|
|                                   |   | For the nine months ended September 30, |
|                                   |   | 2010                                    |   | 2009   |
| Expected life (years)                  |   | 5.4                                     |   |   | 5.4     |   |
| Expected volatility                    |   | 91.7                                    | %      |   | 85.3    | %      |
| Expected dividend yield                |   | —                                 |   |   | — |   |
| Risk-free interest rate                |   | 1.6                                     | %      |   | 2.5     | %      |
| Weighted average fair value of options |   |                                    |   |   |
| granted during the period              |   | $                                       | 0.45   |   |    | $      | 0.30 |   |

----

|                                           |        |                  |        |                                           |         |                                                     |        |                                          |        |        |        |         |        |
|-------------------------------------------|--------|------------------|--------|-------------------------------------------|---------|-----------------------------------------------------|--------|------------------------------------------|--------|--------|--------|---------|--------|
|                                      |   | Number of Shares |   | Weighted Average Exercise Price Per Share |    | Weighted Average remaining Contractual Life (years) |   | Aggregate Intrinsic Value (in thousands) |
| Outstanding balance at December 31, 2009  |   | 5,782,100        |   |                                      | $       | 2.54                                                |   |                                     |   |   |   |
| Granted                                   |   | 1,135,000        |   |                                      | 0.63    |                                                |   |                                     |   |   |
| Exercised                                 |   | —          |   |                                      | — |                                                |   |                                     |   |   |
| Expired                                   |   | (271,250         | )      |                                      | 6.28    |                                                |   |                                     |   |   |
| Forfeitures                               |   | (576,250         | )      |                                      | 1.06    |                                                |   |                                     |   |   |
| Outstanding balance at September 30, 2010 |   | 6,069,600        |   |                                      | $       | 2.16                                                |   |                                     | 6.9    |   | $      | 347     |   |
| Options exercisable at September 30, 2010 |   | 2,618,975        |   |                                      | $       | 3.74                                                |   |                                     | 4.8    |   | $      | — |   |

----

|                            |        |             |        |          |        |              |        |         |        |        |        |   |         |        |
|----------------------------|--------|-------------|--------|----------|--------|--------------|--------|---------|--------|--------|--------|---|---------|--------|
|                       |   | Weighted    |   |     |   |         |   |    |
|                       |   | Average     |   | Gross    |   |         |   |    |
|                       |   | Useful Life |   | Carrying |   | Accumulated  |   | Net     |
| (dollars in thousands)     |   | (years)     |   | Amount   |   | Amortization |   | Balance |
| At September 30, 2010:     |   |        |   |     |   |         |   |    |
| Non-competition agreements |   | 4.7         |   | $        | 8,738  |         |   | $       | 8,738  |   |   | $ | — |   |
| Customer relationships     |   | 9.7         |   | 12,502   |   |         | 11,958 |    |   | 544    |   |
| Trademarks and trade names |   | 15.7        |   | 487      |   |         | 401    |    |   | 86     |   |
|                       |   |        |   | $        | 21,727 |         |   | $       | 21,097 |   |   | $ | 630     |   |
| At December 31, 2009:      |   |        |   |     |   |         |   |    |
| Non-competition agreements |   | 4.7         |   | $        | 8,738  |         |   | $       | 8,738  |   |   | $ | — |   |
| Customer relationships     |   | 9.7         |   | 12,502   |   |         | 11,675 |    |   | 827    |   |
| Trademarks and trade names |   | 15.7        |   | 487      |   |         | 382    |    |   | 105    |   |
|                       |   |        |   | $        | 21,727 |         |   | $       | 20,795 |   |   | $ | 932     |   |

----

|                   |                                   |                    |                                    |
|-------------------|-----------------------------------|--------------------|------------------------------------|
| (In millions)     |  Balance atDecember 31, 2009 |  2010Payments |  Balance atSeptember 30, 2010 |
| Lease Obligations | $0.3                              | $(0.2)             | $0.1                               |

|                   |                             |              |                              |
|-------------------|-----------------------------|--------------|------------------------------|
| (In millions)     | Balance atDecember 31, 2009 | 2010Payments | Balance atSeptember 30, 2010 |
| Lease Obligations | $0.1                        | -            | $0.1                         |

----

|                                |                                                                                                                                              |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| •     | pay any dividends or distributions on, or purchase, redeem or retire any shares of any class of its capital stock or other equity interests; |

|                                |                                |
|--------------------------------|--------------------------------|
| •     | incur additional indebtedness; |

|                                |                                                                                                |
|--------------------------------|------------------------------------------------------------------------------------------------|
| •     | sell or otherwise dispose of any of its assets, other than in the ordinary course of business; |

|                                |                             |
|--------------------------------|-----------------------------|
| •     | create liens on its assets; |

|                                |                                                     |
|--------------------------------|-----------------------------------------------------|
| •     | enter into any sale and leaseback transactions; and |

----

|                                |                                                                                                              |
|--------------------------------|--------------------------------------------------------------------------------------------------------------|
| •     | enter into transactions with any of its affiliates on other than an arm's-length or no less favorable basis. |

----

----

----

|        |                                                                                       |
|--------|---------------------------------------------------------------------------------------|
| ITEM 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations |

|                                |                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Portamedic - performs paramedical and medical examinations of individuals, primarily on behalf of insurance companies in connection with the offering or rating of insurance coverage (mainly life insurance), along with medical examinations of health plan participants in order to provide medical information on plan members to the plan sponsors; |

|                                |                                                                                                                                                                                                                                                                                         |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Heritage Labs - performs tests of blood, urine and/or oral fluid specimens, primarily generated in connection with the paramedical exams and wellness screenings performed by our Portamedic and Health & Wellness service lines, and assembles and sells specimen collection kits; |

|                                |                                                                                                                                                                                                                                                                              |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Health & Wellness - collects health information via on-site biometric screenings, self-collection laboratory test kits and health risk assessments for health management companies, including wellness companies, disease management organizations and health plans; and |

|                                |                                                                                                                                                                                                                                                           |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Hooper Holmes Services - provides telephone interviews of insurance candidates, retrieval of medical records and inspections, risk management solutions and underwriting services for simplified issue products and products requiring full underwriting. |

----

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In April 2010, we launched a new electronic system for capturing paramedical exam information which utilizes wireless mobile netbooks, linked to secure corporate servers. This new “iParamed e-Exam” service delivers a complete digital case file for any life insurance applicant located anywhere in the U.S., while also providing  our customers with real-time quality assurance at the time of exam. The cycle time required for insurance carriers to process applications is also expected to be reduced.  During the third quarter of 2010, we began deployment of mobile netbooks to our examiners to service iParamed e-Exam customers and expect to have 500 netbooks deployed by December 2010. |

|                                |                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In the second quarter of  2010, we began providing examination services to several health insurance providers. We provide these services using our network of medical professionals. The purpose of these examinations is to enable health insurance companies to evaluate risk and insurability for health insurance applicants. |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In the fourth quarter of  2009, we expanded our service offering of providing medical exam assessments to senior individuals who are enrolled in Medicare Advantage healthcare plans. We provide these services utilizing our network of licensed and trained physicians, nurse practitioners and physician assistants. The purpose of these medical assessments is to provide health insurance payors with health information on their plan members to assist in validating pricing/reimbursement information and to provide information used in quality improvement and disease management initiatives. |

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In the third quarter of 2009, we introduced a new appointment scheduling option called Instant Scheduling.  It allows insurance agents, while completing the policy application with the applicant, to immediately schedule the examination utilizing our centralized scheduling center.  The new process significantly reduces the cycle time of policy application to policy issuance, which benefits the applicant, agent/broker and insurance carrier. |

|                                |                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | We introduced our National Broker & General Agency service program which includes specialized training of our field sales representatives to market to this specific distribution channel. To serve these customers, we have implemented new case management services which link our ordering and imaging systems to many agency management tools. |

|                                |                                                                                                                                                                                                                                                                                                      |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | All of our Portamedic branch offices are now utilizing managed scheduling. As a result of implementing managed scheduling, the time required to schedule an examination has been reduced significantly relative to past procedures where examiners scheduled their own appointments with applicants. |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | We will begin the rollout of our new customer service order tracking IT system at several of our larger branch offices in December 2010. Based on our current project plan timetable, we now expect to complete the conversion of the systems at all of our branches by March 31, 2011. The change in the estimated completion date from the end of December 2010 to March 31, 2011 is due to additional functionality added to the project plan. The new system is expected to improve the speed, accuracy and consistency of services provided to our Portamedic customers, while lowering our future operating costs.  This new customer service system is expected to cost approximately $2.0 million to develop, including implementation costs. As a result of the development of this new system, we reduced the estimated useful life of our old system as appropriate. This reduction in useful life accelerated our depreciation expense (non-cash charge) by nil and approximately $0.6 million in the third quarter of 2010 and 2009, respectively. We believe that our investment in this new customer service system will enhance the quality of service to our customers, while improving productivity and decreasing future cash outlay. |

|                                |                                                                                                                                                                                                                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | We continue to take steps to strengthen our local sales force including hiring additional sales representatives, streamlining our sales tracking systems, improving sales training, and focusing sales incentives on increases in paramedical exams completed (i.e., unit goals). |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Heritage Labs continues to focus on data modeling to gain a better understanding of the true mortality consequences of the laboratory tests that we provide to the insurance industry. Our objective is to assist our clients in their ability to develop new insurance products and establish more accurate premium rating or pricing techniques using the lab mortality data that we have developed. We have also begun to develop risk scores to help our insurance clients better understand the mortality implications between and among interactions of multiple tests related to specific disease states. We believe that the mortality data we are providing are unique and more complex than the data being provided by our competitors. We believe we will be able to leverage the value of the data we supply to gain new business in 2010.  Although we are evaluating whether to sell this data, our primary strategy is to provide this data to our customers, with the expectation of securing increased lab testing from the customer. |

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In December 2009, we hired a new Chief Operating Officer to oversee the operations of our Heritage Labs and Health & Wellness service lines. This individual has assisted in the implementation of actions to improve our processes and reduce costs, including the outsourcing of several kit assembly functions, obtaining price reductions for kit raw materials and lab test reagents, along with a consolidation of certain Heritage Labs and Health & Wellness job functions. |

|                                |                                                                                                                                                                                                                                                                                              |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Heritage Labs continues to expand its kit assembly products and services. Heritage Labs is an FDA-registered Class I and Class II medical device assembler. Of the three laboratories providing testing services to the insurance industry, only Heritage Labs is licensed to assemble kits. |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | Heritage Labs is marketing a line of self-collected finger stick test kits directly to customers, under the trade name “Appraise.” These kits test hemoglobin A1c. The hemoglobin A1c test is particularly important for diabetics, who must regularly monitor their hemoglobin A1c levels. Heritage Labs uses two blood testing methods for hemoglobin A1c, one for testing whole blood specimens and the other for testing dried blood spots. The test kits are currently available in retail locations including Wal-Mart, Rite Aid, Walgreens and other locations nationwide. |

|                                |                                                                                                                                                                                                                                       |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | In 2009, Heritage Labs moved its lab facilities to a new, larger location which is expected to increase productivity and enable new service/product offerings, including offerings focusing outside the paramedical exam marketplace. |

----

|                                |                                                                 |
|--------------------------------|-----------------------------------------------------------------|
| •     | the number of paramedical examinations performed by Portamedic; |

|                                |                                                  |
|--------------------------------|--------------------------------------------------|
| •     | the average revenue per paramedical examination; |

|                                |                                                                 |
|--------------------------------|-----------------------------------------------------------------|
| •     | time service performance, from examination order to completion; |

|                                |                                                                                                                                                                                     |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | the MIB Life Index data and research data from a national insurance industry consulting company, which represents an indicator of the level of life insurance application activity; |

|                                |                                                                     |
|--------------------------------|---------------------------------------------------------------------|
| •     | the number of health screenings completed by Health & Wellness; |

|                                |                                                                   |
|--------------------------------|-------------------------------------------------------------------|
| •     | the number of tele-interviewing/underwriting reports we generate; |

|                                |                                                  |
|--------------------------------|--------------------------------------------------|
| •     | the number of specimens tested by Heritage Labs; |

|                                |                                          |
|--------------------------------|------------------------------------------|
| •     | the average revenue per specimen tested; |

|                                |                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------|
| •     | budget to actual performance at the branch level as well as in the aggregate; and |

|                                |                                          |
|--------------------------------|------------------------------------------|
| •     | customer and product line profitability. |

----

|        |                              |        |                                          |        |                                         |          |        |        |        |         |         |          |        |         |         |        |        |       |         |        |        |       |    |
|--------|------------------------------|--------|------------------------------------------|--------|-----------------------------------------|----------|--------|--------|--------|---------|---------|----------|--------|---------|---------|--------|--------|-------|---------|--------|--------|-------|----|
|   |   (in thousands)   |   | For the Three Months Ended September 30, |   | For the Nine Months Ended September 30, |
|   |                         | 2010   |                                     | 2009   |                                    | % Change |   | 2010   |   | 2009    |    | % Change |
|   |                         |   |                                     |   |                                    |     |   |   |   |    |    |     |   |
|   | Portamedic                   |   | $                                        | 28,152 |                                    |     | $      | 32,432 |   |    | (13.2   | )%       |   | $       | 89,355  |   |   | $     | 102,072 |   |   | (12.5 | )% |
|   | Heritage Labs                |   | 3,285                                    |   |                                    | 3,571    |   |   | (8.0   | )%      |    | 10,043   |   |    | 11,318  |   |   | (11.3 | )%      |
|   | Health and Wellness          |   | 3,681                                    |   |                                    | 2,486    |   |   | 48.1   |  % |    | 8,521    |   |    | 6,837   |   |   | 24.6  |  % |
|   | Hooper Holmes Services       |   | 5,687                                    |   |                                    | 5,925    |   |   | (4.0   | )%      |    | 16,615   |   |    | 19,187  |   |   | (13.4 | )%      |
|   |    Subtotal   |   | 40,805                                   |   |                                    | 44,414   |   |   |   |    | 124,534 |     |   | 139,414 |    |   |   |
|   | Intercompany eliminations(a) |   | (459                                     | )      |                                    | (624     | )      |   |   |    | (1,556  | )        |   | (1,977  | )       |   |   |
|   |    Total      |   | $                                        | 40,346 |                                    |     | $      | 43,790 |   |    | (7.9    | )%       |   | $       | 122,978 |   |   | $     | 137,437 |   |   | (10.5 | )% |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | decreased paramedical examinations performed in the third quarter of 2010 of approximately 14.2% (313,000 in the third quarter of 2010, or 4,887 per day, vs. 365,000 in the third quarter of 2009, or 5,699 per day), and in the nine month period ended September 30, 2010 of approximately 13.0% (1,003,000 in the nine month period ended September 30, 2010, or 5,253 per day, vs. 1,154,000 in the nine month period ended September 30, 2009, or 6,041 per day); and |

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | higher average revenue per paramedical examination in the third quarter of 2010 of approximately 0.3% as compared to the third quarter of 2009 ($90.22 in the third quarter of 2010 vs. $89.93 in the third quarter of 2009), and in the nine month period ended September 30, 2010, a lower average revenue per paramedical examination of approximately 0.3% ($89.37 in the nine month period ended September 30, 2010 vs. $89.65 in the nine month period ended September 30, 2009) |

----

----

|                                     |        |                                          |        |                                         |        |        |        |                   |        |        |        |                   |        |        |        |                   |         |        |        |        |        |        |      |         |        |        |      |   |
|-------------------------------------|--------|------------------------------------------|--------|-----------------------------------------|--------|--------|--------|-------------------|--------|--------|--------|-------------------|--------|--------|--------|-------------------|---------|--------|--------|--------|--------|--------|------|---------|--------|--------|------|---|
| (in thousands)                      |   | For the Three Months Ended September 30, |   | For the Nine Months Ended September 30, |
|                                |   | 2010                                     |   | As a % ofRevenues                       |   | 2009   |   | As a % ofRevenues |   | 2010   |   | As a % ofRevenues |   | 2009   |   | As a % ofRevenues |
| Portamedic/Health & Wellness    |   | $                                        | 23,932 |                                    |   | 75.2   | %      |              | $      | 25,632 |   |              | 73.4   | %      |   | $                 | 72,281  |   |   | 73.8   | %      |   | $    | 79,147  |   |   | 72.7 | % |
| Heritage Labs                       |   | 2,027                                    |   |                                    | 61.7   | %      |   | 2,336             |   |   | 65.4   | %                 |   | 6,372  |   |              | 63.4    | %      |   | 7,294  |   |   | 64.4 | %       |
| Hooper Holmes Services              |   | 4,583                                    |   |                                    | 80.6   | %      |   | 4,952             |   |   | 83.6   | %                 |   | 13,570 |   |              | 81.7    | %      |   | 16,164 |   |   | 84.2 | %       |
|  Subtotal                      |   | 30,542                                   |   |                                    |   |   | 32,920 |              |   |   |   | 92,223            |   |   |   |              | 102,605 |   |   |   |
| Intercompany eliminations (a)  |   | (478                                     | )      |                                    |   |   | (648   | )                 |   |   |   | (1,470            | )      |   |   |              | (2,002  | )      |   |   |
|      Total |   | $                                        | 30,064 |                                    |   | 74.5   | %      |              | $      | 32,272 |   |              | 73.7   | %      |   | $                 | 90,753  |   |   | 73.8   | %      |   | $    | 100,603 |   |   | 73.2 | % |

----

|                                              |        |                                          |        |          |        |                                         |        |          |        |      |        |               |        |   |        |        |        |   |        |        |        |   |       |        |
|----------------------------------------------|--------|------------------------------------------|--------|----------|--------|-----------------------------------------|--------|----------|--------|------|--------|---------------|--------|---|--------|--------|--------|---|--------|--------|--------|---|-------|--------|
| (in thousands)                               |   | For the Three Months Ended September 30, |   | Decrease |   | For the Nine Months Ended September 30, |   | Decrease |
|                                         |   | 2010                                     |   | 2009     |   | 2010 vs. 2009                           |   | 2010     |   | 2009 |   | 2010 vs. 2009 |
| Selling, general and administrative expenses |   | $                                        | 10,607 |     |   | $                                       | 11,867 |     |   | $    | 1,260  |          |   | $ | 33,292 |   |   | $ | 38,360 |   |   | $ | 5,068 |   |

|                                |                                                                                                                          |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| •     | health insurance, workers compensation and general insurance costs totaling $0.7 million and $2.0 million, respectively; |

|                                |                                                                                                                                                                                                        |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | accelerated depreciation expense related to the reduction of the estimated useful life of our current customer service order tracking IT systems totaling $0.6 million and $1.5 million, respectively; |

|                                |                                                                                                                    |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------|
| •     | consulting costs associated with a strategic advisor retained in 2009 totaling nil and $0.5 million, respectively; |

|                                |                                                                                                     |
|--------------------------------|-----------------------------------------------------------------------------------------------------|
| •     | incentive compensation expense totaling nil and $0.1 million, respectively;     |

|                                |                                                                                                                   |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------|
| •     | Portamedic regional and administrative salaries and related expenses totaling nil and $0.1 million, respectively; |

|                                |                                                                                                                                  |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| •     | audit and bank fees, and amortization expense totaling $0.03 million and $0.4 million, respectively; and     |

|                                |                                                                                                                                   |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| •     | moving expense associated with Heritage Labs' move to a new facility in January 2009 totaling nil and $0.2 million, respectively. |

----

|                                |                                                     |
|--------------------------------|-----------------------------------------------------|
| •     | an increase in accounts receivable of $1.2 million; |

|                                |                                                                                                                                                                                       |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | a decrease in accounts payable, accrued expense and other long-term liabilities (including restructuring payments related to employee severance of $1.2 million) of $0.5 million; and |

|                                |                                       |
|--------------------------------|---------------------------------------|
| •     | capital expenditures of $3.0 million. |

|                                |                                                 |
|--------------------------------|-------------------------------------------------|
| •     | a decrease in other assets of $1.1 million; and |

|                                |                                              |
|--------------------------------|----------------------------------------------|
| •     | receipt of a $1.5 million income tax refund. |

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | an increase in accounts receivable of $1.2 million. Our consolidated days sales outstanding (“DSO”), measured on a rolling 90-day basis, was 48 days at September 30, 2010, compared to 41 days at December 31, 2009 and 47 days at September 30, 2009. Historically, our accounts receivable balances and our DSO are at their lowest point in December as many of our customers utilize the remainder of their operating budgets before their year-end budget close-out. Historically, we experience an increase in DSO starting in the first quarter of each year, in comparison to the prior year-end DSO position. We believe our persistent collection efforts, along with our continued focus on electronic customer billing will reduce our DSO over the remainder of the year, as has historically been the case. Our consolidated allowance for doubtful accounts, which includes a reserve for revenue reductions, declined approximately $0.2 million since December 31, 2009, of which $0.05 million and $0.2 million was credited to revenue during the three and nine month periods ended September 30, 2010, respectively; |

|                                |                                                                                                       |
|--------------------------------|-------------------------------------------------------------------------------------------------------|
| •     | a decrease in accounts payable, accrued expenses and other long-term liabilities of $0.5 million; and |

|                                |                                             |
|--------------------------------|---------------------------------------------|
| •     | a decrease in other assets of $1.1 million. |

----

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •     | a decrease in accounts receivable of $2.4 million, primarily due to increased Portamedic cash collections. Our consolidated DSO, measured on a rolling 90-day basis, was 47 days at September 30, 2009, compared to 48 days at December 31, 2008 and 55 days at September 30, 2008. Historically, our accounts receivable balances and our DSO are at their lowest point in December as many of our customers utilize the remainder of their operating budgets before their year-end budget close-out. Our DSO from December 31, 2008 to September 30, 2009 improved 1 day compared to an increase of 9 days for the same period of the prior year. We believe our increased collection efforts in 2009, along with our continued focus on electronic customer billing, are the primary drivers of our improvement in our 2009 DSO relative to our historic experience. As a result of these improvements, our allowance for doubtful accounts, which includes a reserve for revenue reductions, declined approximately $1.5 million since December 31, 2008, of which  $0.2 million and $0.4 million was credited to revenue during the three and nine month periods ended September 30, 2009, respectively. |

----

|                                |                                                                                                                                              |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| •     | pay any dividends or distributions on, or purchase, redeem or retire any shares of any class of our capital stock or other equity interests; |

|                                |                                |
|--------------------------------|--------------------------------|
| •     | incur additional indebtedness; |

|                                |                                                                                                |
|--------------------------------|------------------------------------------------------------------------------------------------|
| •     | sell or otherwise dispose of any of our assets, other than in the ordinary course of business; |

|                                |                             |
|--------------------------------|-----------------------------|
| •     | create liens on our assets; |

|                                |                                                     |
|--------------------------------|-----------------------------------------------------|
| •     | enter into any sale and leaseback transactions; and |

|                                |                                                                                                              |
|--------------------------------|--------------------------------------------------------------------------------------------------------------|
| •     | enter into transactions with any of our affiliates on other than an arm's-length or no less favorable basis. |

----

----

|        |                                                            |
|--------|------------------------------------------------------------|
| ITEM 3 | Quantitative and Qualitative Disclosures About Market Risk |

|        |                         |
|--------|-------------------------|
| ITEM 4 | Controls and Procedures |

----

|        |                   |
|--------|-------------------|
| ITEM 1 | Legal Proceedings |

|         |              |
|---------|--------------|
| ITEM 1A | Risk Factors |

----

|        |                                                             |
|--------|-------------------------------------------------------------|
| ITEM 2 | Unregistered Sales of Equity Securities and Use of Proceeds |

|        |                                 |
|--------|---------------------------------|
| ITEM 3 | Defaults Upon Senior Securities |

|        |                      |
|--------|----------------------|
| ITEM 4 | Removed and Reserved |

|        |                   |
|--------|-------------------|
| ITEM 5 | Other Information |

|        |          |
|--------|----------|
| ITEM 6 | Exhibits |

|             |        |                                                                                                                                           |
|-------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Exhibit No. |   | Description of Exhibit                                                                                                                    |
|        |   |                                                                                                                                      |
| 31.1        |   | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.                            |
|        |   |                                                                                                                                      |
| 31.2        |   | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.                            |
|        |   |                                                                                                                                      |
| 32.1        |   | Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. |
|        |   |                                                                                                                                      |
| 32.2        |   | Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. |

----

|        |        |                                                                                               |        |
|--------|--------|-----------------------------------------------------------------------------------------------|--------|
|   |   | By: /s/ Ransom J. Parker                                                                      |   |
|   |   | Ransom J. Parker                                                                              |   |
|   |   | Chief Executive Officer and President(Principal Executive Officer)                            |   |
|   |   |                                                                                          |   |
|   |   | By: /s/ Michael J. Shea                                                                       |   |
|   |   | Michael J. Shea                                                                               |   |
|   |   | Senior Vice President and Chief Financial Officer(Principal Financial and Accounting Officer) |   |